Patent classifications
C12Y603/02019
Modified polynucleotides for the production of cosmetic proteins and peptides
The invention relates to cosmetic mRNAs encoding elastin, and methods of using such mRNAs.
PROTEIN EXPRESSION STRAINS
The invention provides an improved host strain for production of desired protein.
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
IN VIVO PRODUCTION OF PROTEINS
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Modified polynucleotides for the production of proteins
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Modified polynucleotides for the production of biologics and proteins associated with human disease
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
MUTATIONS OF THE PARKIN GENE, COMPOSITIONS, METHODS AND USES
The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Modified polynucleotides encoding hepatitis A virus cellular receptor 2
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
TARGETED DEGRADATION OF ALPHA-SYNUCLEIN
The present invention relates to a proteasomal degradation protein complex that comprises an E3 ubiquitin ligase component tethered to an -synuclein-specific polypeptide binder for degradation of -synuclein. The present invention also comprises a mechanism of action, composition and related methods for the treatment of neurological disorders including synucleopathies.